Valuation: EDAP TMS S.A.

Capitalization 156M 133M 122M 115M 214M 14.92B 215M 1.45B 566M 7.08B 585M 573M 24.61B P/E ratio 2026 *
-4.66x
P/E ratio 2027 * -6.24x
Enterprise value 156M 133M 122M 115M 214M 14.92B 215M 1.45B 566M 7.08B 585M 573M 24.61B EV / Sales 2026 *
2.08x
EV / Sales 2027 * 1.95x
Free-Float
32.89%
Yield 2026 *
-
Yield 2027 * -
1 day+1.96%
1 week+15.72%
Current month+25.30%
1 month+25.11%
3 months-10.92%
6 months+96.23%
Current year+26.44%
1 week 3.89
Extreme 3.89
4.3
1 month 3.12
Extreme 3.12
4.3
Current year 3.1
Extreme 3.1
5.05
1 year 1.21
Extreme 1.21
5.05
3 years 1.21
Extreme 1.21
12.09
5 years 1.21
Extreme 1.21
12.65
10 years 1.21
Extreme 1.21
12.65
Manager TitleAgeSince
Chief Executive Officer 64 01/05/2023
Director of Finance/CFO 55 01/01/2024
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 64 01/05/2023
Chairman 64 01/09/2024
Director/Board Member 62 08/07/2024
Change 5d. change 1-year change 3-years change Capi.($)
+1.96%+15.72%+90.39%-62.69% 156M
-2.89%-5.69%+3.98%-14.99% 166B
+0.09%-4.31%-23.35%+41.60% 153B
-0.16%-5.11%-15.57%-26.99% 117B
-1.92%-5.25%-48.46%-0.52% 78.87B
+2.08%-2.18%+7.80%-8.74% 46.86B
+1.52%+1.21%-28.68%-37.34% 44.33B
-4.91%-4.18%-6.71%+23.59% 32.89B
-0.14%-4.21%-2.32%-11.57% 31.86B
-0.27%-3.90%-28.78%-45.91% 29.55B
Average -0.47%-2.37%-5.17%-14.35% 70.08B
Weighted average by Cap. -0.93%-4.72%-15.13%-3.35%

Financials

2026 *2027 *
Net sales 74.97M 64.02M 58.66M 55.46M 103M 7.17B 103M 698M 272M 3.4B 281M 275M 11.83B 79.81M 68.16M 62.45M 59.04M 109M 7.64B 110M 744M 289M 3.62B 299M 293M 12.6B
Net income -33.53M -28.63M -26.24M -24.8M -45.93M -3.21B -46.17M -312M -122M -1.52B -126M -123M -5.29B -27.54M -23.52M -21.55M -20.37M -37.72M -2.64B -37.92M -257M -99.88M -1.25B -103M -101M -4.35B
Net Debt - -
Logo EDAP TMS S.A.
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
Employees
310
Date Price Change Volume
13/05/26 4.160 $ +1.96% 15,283
12/05/26 4.080 $ -2.16% 34,375
11/05/26 4.170 $ +0.97% 50,983
08/05/26 4.130 $ -0.72% 65,066
07/05/26 4.160 $ +15.72% 210,739
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.160USD
Average target price
5.833USD
Spread / Average Target
+40.22%

Quarterly revenue - Rate of surprise